# Replimune Group (REPL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/REPL
## Company Profile
- Ticker: REPL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 15.24 USD
- Market cap: 732419130.53 USD
- Last updated: 2026-08-12
## Business Overview
### Oncolytic Immunotherapy Platform
Replimune develops tumor-directed immunotherapies based on engineered herpes simplex virus type 1. The RPx platform is designed to cause immunogenic tumor-cell death and stimulate a systemic antitumor immune response.
### RP1
RP1 is engineered to express a fusogenic protein and GM-CSF and is the company’s lead candidate. A resubmitted BLA seeks approval in melanoma that has failed anti-PD-1 therapy, while the Phase 3 IGNYTE-3 trial serves as a global confirmatory study.
### RP2
RP2 adds additional immune-stimulatory payloads to the RPx backbone. The registration-directed REVEAL Phase 2/3 trial is evaluating it in metastatic uveal melanoma, and separate studies address hepatocellular carcinoma and other liver-focused tumors.
### Transplant-Associated Skin Cancer
The Phase 2 ARTACUS study evaluates RP1 monotherapy in cutaneous squamous cell carcinoma after organ transplantation. This program explores an oncolytic therapy in immunosuppressed patients for whom systemic checkpoint blockade may be difficult to use.
## Why The Stock Is Moving

As of Aug 12, 2026, REPL closed up 11.6% at $15.24. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA action on the resubmitted RP1 BLA targeted for April 10, 2026, followed by a potential launch if approved.
- RP2 monotherapy data planned by year-end 2026.
- Transition of the REVEAL uveal-melanoma study into Phase 2/3 expected in the first quarter of 2027.

## Recent News
- 2026-08-10 12:00 EST — [Replimune Announces Pricing of $150 Million Underwritten Offering](https://biopharmsignal.com/news/REPL/replimune-announces-pricing-of-150-million-underwritten-offering-79edc2e2) — Source: Replimune Group
- 2026-08-06 20:00 EST — [Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen](https://biopharmsignal.com/news/REPL/replimune-announces-fda-accelerated-approval-of-tudriqevtm-in-combination-with-n-9ad39372) — Source: Replimune Group
- 2026-07-30 22:15 EST — [Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma](https://biopharmsignal.com/news/REPL/replimune-announces-favorable-outcome-of-fda-s-cellular-tissue-and-gene-therapie-4ca65fc6) — Source: Replimune Group
- 2026-06-29 12:00 EST — [Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-results-and--829c51fd) — Source: Replimune Group
- 2026-06-26 12:00 EST — [Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma](https://biopharmsignal.com/news/REPL/replimune-announces-fda-acceptance-of-rp1-biologics-license-application-resubmis-9ba52bee) — Source: Replimune Group